Realizing a new life with diabetes.
Location: United States, Ohio, Cleveland
Total raised: $30M
Investors 2
| Date | Name | Website |
| - | T1D Fund | t1dfund.or... |
| - | Quaker Par... | quakerpart... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 05.07.2017 | - | $30M | - |
Mentions in press and media 12
| Date | Title | Description |
| 20.06.2025 | Diasome Pharmaceuticals Completes Enrollment in Phase 2b OPTI-2 Trial of HDV-Insulin Lispro for Type 1 Diabetes | Phase 2b OPTI-2 trial to assess liver-targeted insulin’s ability to reduce hypoglycemia and improve postprandial control using Dexcom G7 CGM data Reaching full enrollment is an important milestone for people who rely on insulin every day, a... |
| 29.02.2024 | Diasome Pharmaceuticals Launches Groundbreaking OPTI-2 Phase 2b Trial in Type 1 Diabetes | CLEVELAND, OH, UNITED STATES, February 29, 2024 /EINPresswire.com/ -- Diasome Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a novel liver targeting drug platform, announced today the initiation of the OPTI-2 P... |
| 20.02.2024 | Diasome Pharmaceuticals Appoints Peter Tollman, Ph.D., as Chairman of the Board | CLEVELAND, OH, UNITED STATES, February 20, 2024 /EINPresswire.com/ -- Diasome Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a novel hepatocyte cell drug targeting platform, today announced the appointment of P... |
| 07.12.2023 | Diasome Pharmaceuticals Announces First Closing of Series C Financing Round | Diasome Secures Series C Funding with Eli Lilly Participation CLEVELAND, OH, USA, December 7, 2023 /EINPresswire.com/ -- Diasome Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company that leverages a novel hepatocyte cell target... |
| 24.10.2023 | Former Novo Nordisk Executive, Dr. Todd Hobbs, joins Diasome Pharmaceuticals as Chief Medical Officer | Dr. Todd Hobbs, Former North American Chief Medical Officer at Novo Nordisk, to Guide Diasome's HDV Platform Expansion The Fund is proud to work alongside the company’s management team – including Dr. Hobbs – as they advance their high impa... |
| 21.06.2023 | Diasome's CMO, Dr. Marc Penn, to Unveil Innovative Diabetes Research at ADA Scientific Sessions | Our data demonstrate that serotonin, 95% of which is made by the gut and is released in response to food ingestion, is a likely candidate to be the elusive portal factor” — Dr. Penn CLEVELAND , OH, UNITED STATES, June 21, 2023/EINPresswire.... |
| 02.06.2022 | Diasome's HDV-Insulin demonstrates substantial Level 2 hypoglycemia reductions in setting of increased insulin use | The OPTI-1 trial shows increasing liver-targeted bolus insulin restores liver physiology allowing subjects to decrease Level 2 hypoglycemia by 50% at nighttime The OPTI-1 study results demonstrate that insulinizing the liver at mealtime, as... |
| 06.07.2017 | Diasome Pharmaceuticals Lands $30M | CLEVELAND, OH, Diasome Pharmaceuticals, a developer of treatments for diabetes and other metabolic conditions, has agreed to raise up to $30 million in funding. >> Click here for more funding data on Diasome Pharmaceuticals >&g... |
| 06.07.2017 | Term Sheet — Thursday, July 6 | THREE UNRELATED THINGS FALSE START: The finance world experienced a big letdown yesterday, after reports that JP Morgan might enter the bidding for Worldpay, a UK-based payment processor worth nearly $10 billion. Paid Content Your company m... |
| 05.07.2017 | Diasome Pharmaceuticals Raises $30M in Funding | Diasome Pharmaceuticals, Inc., a Cleveland, OH-based innovative life sciences technology company focused on the development of novel therapies for the treatment of diabetes and other metabolic conditions, raised up to $30m in funding. The r... |
Show more